Jiangsu, China

Bingliang Chen


Average Co-Inventor Count = 4.7

ph-index = 1


Location History:

  • Suzhou, CN (2022)
  • Jiangsu, CN (2022 - 2023)

Company Filing History:


Years Active: 2022-2023

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Bingliang Chen: Innovator in Antibody Development

Introduction

Bingliang Chen, an inventive mind based in Jiangsu, China, has made significant contributions to the field of biotechnology with his innovative research and development of therapeutic antibodies. With a portfolio of four patents, his work primarily focuses on the therapeutic applications of antibodies in cancer treatment.

Latest Patents

Among his latest patents, two stand out for their potential impact on the medical field:

1. **Anti-CD47 Antibody and Use Thereof** - This invention pertains to novel antibodies and antibody fragments that selectively bind to integrin-associated proteins, specifically CD47. It encompasses a composition comprising these antibodies or fragments, along with nucleic acids encoding them, host cells, and various diagnostic and therapeutic uses.

2. **Anti-PD-L1 Antibody and Uses Thereof** - This patent involves a novel antibody and its fragments that target PD-L1. Similar to the previous patent, this invention includes a nucleic acid sequence, host cell applications, and proposed therapeutic and diagnostic uses, particularly focusing on a combined treatment strategy with other therapies.

Career Highlights

Bingliang Chen has worked with Innovent Biologics (Suzhou) Co., Ltd., a leading biotechnology company dedicated to developing innovative biologic medicines. His role at the company has allowed him to experiment and bring to fruition groundbreaking research in antibody therapies.

Collaborations

Collaboration has been key to Chen's success, and he has worked alongside professionals such as Junjian Liu and Dandan Liu. Their combined expertise has fostered an innovative environment that has led to significant advancements in antibody research and development.

Conclusion

Bingliang Chen is a valuable inventor whose innovations in antibody development have the potential to transform cancer treatment. His patent portfolio reflects a commitment to advancing therapeutic solutions through collaboration and scientific ingenuity, signaling a promising future in the field of biotechnology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…